SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

GlaxoSmithKline Pharmaceuticals informs about outcome of board meeting

13 May 2025 Evaluate
GlaxoSmithKline Pharmaceuticals has informed that a meeting of the Board of Directors of the Company was held today, i.e. 13th May 2025 and transacted the following business: Pursuant to Regulation 33 of LODR the following documents are enclosed- Approved Audited Financial Statements & Results (Standalone and Consolidated) for the quarter & year ended 31st March 2025; Auditors Report for the year ended 31st March 2025; Statement of Assets and Liabilities; Certificate for unmodified opinion The Board has recommended a final dividend of Rs 42 per equity share on face value of Rs 10 each for the year ended 31st March 2025, subject to approval of members at 100th Annual General Meeting. 

The above information is a part of company’s filings submitted to BSE.

Glaxosmithkline Phar Share Price

2409.85 16.60 (0.69%)
13-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1652.00
Dr. Reddys Lab 1235.20
Cipla 1211.30
Zydus Lifesciences 923.10
Lupin 2312.35
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×